Price increase for Evonik’s PMMA molding compounds
Effective January 1, 2015, Evonik Cyro LLC will increase the prices of its PMMA molding compounds, which it markets under the ACRYLITE® and ACRYMID® trademarks, and its modified acrylic-based compounds marketed under the CYROLITE®, CYREX®, CYPROVU® and XT® trademarks globally. As far as permissible under existing agreements and according to the product type the increase will amount to 3 – 8 percent.
Evonik Industries is a worldwide manufacturer of PMMA products sold under the ACRYLITE® and ACRYMID® in the Americas, and under the PLEXIGLAS® and PLEXIMID® trademarks on the European, Asian, African and Australian continents. Modified acrylic-based compounds are marketed under the CYROLITE®, CYREX®, CYROVU® and XT® trademarks globally.
For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america. Please visit us on Facebook at www.facebook.com/EvonikNorthAmerica. Follow us on Twitter at http://twitter.com/EvonikN_America.
Company information
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €2.0 billion.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.